Kiora Pharmaceuticals price to sales ratio KPRX

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 0.6×; May 2025
9-year median: 12.6×
9-year range: 0.5× to 38.5×
Peer median: 0.9×

Kiora Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2025, at 0.6×.

On the days it had one over the last 9 years, its median was 12.6×, from 0.5× in Apr 2025 to 38.5× in Dec 2017.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	0.6×	0.5×	0.6×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	8.7×	6.2×	13.0×
2019	12.6×	2.5×	13.9×
2018	12.5×	8.8×	38.2×
2017	32.4×	14.5×	38.5×

Against its peers

Companies in Drug Manufacturers - General nearest Kiora Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
KPRXKiora Pharmaceuticals	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Kiora Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.